Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell-Redirecting Immunotherapies.

Blood cancer discovery - 3 Nov 2025

Papadimitriou Marios, Ahn Sungwoo, Diamond Benjamin T, Lee Holly, McIntyre John B, Truger Marietta, Durante Michael A, Ziccheddu Bachisio, Osz Katalin, Landgren Ola, Rasche Leo, Bahlis Nizar J, Neri Paola, Maura Francesco

Abstract excerpt

Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CAR-T cell therapy research

Share to Immunotherapy, Adoptive

Share to Multiple Myeloma

Share to Multiple Myeloma Research and Treatments

Share to Mutation

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 40906971
DOI: 10.1158/2643-3230.BCD-25-0005
PMCID: PMC12514755

Genes

TNFRSF17

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell-Redirecting Immunotherapies.PMID 40906971Read ↗

Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapiesSemantic proximity Read ↗

Acquired and Selected: Tracking Antigen Escape during T Cell-Redirecting Therapies in Multiple Myeloma.Semantic proximity Read ↗

Multi-Omic Profiling Reveals Epigenetic Drivers of Immunotherapy Resistance in Multiple MyelomaSemantic proximity Read ↗

Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MMSemantic proximity Read ↗

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaSemantic proximity Read ↗

Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myelomaSemantic proximity Read ↗

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.Semantic proximity Read ↗

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.Semantic proximity Read ↗

Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.Semantic proximity Read ↗

Tumor Intrinsic Mechanisms of Antigen Escape to Anti-BCMA and Anti-GPRC5D Targeted Immunotherapies in Multiple MyelomaSemantic proximity Read ↗

Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma.Semantic proximity Read ↗

Accelerated single cell seeding in relapsed multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.